1. Home
  2. LGCY vs HLVX Comparison

LGCY vs HLVX Comparison

Compare LGCY & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCY
  • HLVX
  • Stock Information
  • Founded
  • LGCY 2009
  • HLVX 2020
  • Country
  • LGCY United States
  • HLVX United States
  • Employees
  • LGCY N/A
  • HLVX N/A
  • Industry
  • LGCY
  • HLVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGCY
  • HLVX Health Care
  • Exchange
  • LGCY NYSE
  • HLVX Nasdaq
  • Market Cap
  • LGCY 87.3M
  • HLVX 83.7M
  • IPO Year
  • LGCY 2024
  • HLVX 2022
  • Fundamental
  • Price
  • LGCY $7.17
  • HLVX $1.90
  • Analyst Decision
  • LGCY Strong Buy
  • HLVX Hold
  • Analyst Count
  • LGCY 2
  • HLVX 5
  • Target Price
  • LGCY $10.65
  • HLVX $2.33
  • AVG Volume (30 Days)
  • LGCY 42.2K
  • HLVX 295.3K
  • Earning Date
  • LGCY 05-15-2025
  • HLVX 05-08-2025
  • Dividend Yield
  • LGCY N/A
  • HLVX N/A
  • EPS Growth
  • LGCY 44.62
  • HLVX N/A
  • EPS
  • LGCY 0.58
  • HLVX N/A
  • Revenue
  • LGCY $52,722,310.00
  • HLVX N/A
  • Revenue This Year
  • LGCY $33.77
  • HLVX N/A
  • Revenue Next Year
  • LGCY $24.88
  • HLVX N/A
  • P/E Ratio
  • LGCY $12.16
  • HLVX N/A
  • Revenue Growth
  • LGCY 32.68
  • HLVX N/A
  • 52 Week Low
  • LGCY $3.60
  • HLVX $1.34
  • 52 Week High
  • LGCY $10.37
  • HLVX $16.31
  • Technical
  • Relative Strength Index (RSI)
  • LGCY N/A
  • HLVX 60.50
  • Support Level
  • LGCY N/A
  • HLVX $1.81
  • Resistance Level
  • LGCY N/A
  • HLVX $1.94
  • Average True Range (ATR)
  • LGCY 0.00
  • HLVX 0.10
  • MACD
  • LGCY 0.00
  • HLVX 0.00
  • Stochastic Oscillator
  • LGCY 0.00
  • HLVX 79.31

About LGCY LEGACY EDUCATION INC

Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.

About HLVX HilleVax Inc.

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Share on Social Networks: